Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TriSalus Life Sciences (TLSI) EBT (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of EBT data on record, last reported at -$9.8 million in Q4 2025.

  • For Q4 2025, EBT rose 3.52% year-over-year to -$9.8 million; the TTM value through Dec 2025 reached -$39.2 million, down 30.62%, while the annual FY2025 figure was -$39.2 million, 30.56% down from the prior year.
  • EBT reached -$9.8 million in Q4 2025 per TLSI's latest filing, up from -$10.8 million in the prior quarter.
  • Across five years, EBT topped out at $2.8 million in Q1 2022 and bottomed at -$44.3 million in Q4 2022.
  • Average EBT over 4 years is -$11.0 million, with a median of -$9.0 million recorded in 2025.
  • The widest YoY moves for EBT: up 82.39% in 2023, down 678.23% in 2023.
  • A 4-year view of EBT shows it stood at -$44.3 million in 2022, then grew by 19.49% to -$35.7 million in 2023, then soared by 71.68% to -$10.1 million in 2024, then rose by 3.52% to -$9.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$9.8 million in Q4 2025, -$10.8 million in Q3 2025, and -$8.3 million in Q2 2025.